4599.T
StemRIM Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 171.00
−3.39%Sep 11, 2026, 06:41 UTC
Japanese stocks fell on September 11, 2026, with StemRIM leading decliners on the Tokyo Stock Exchange Growth Market after announcing clinical trial results for Redasemtide.
Source:Sep 9, 2026, 07:32 UTC
StemRim announced results of clinical trials for 'Redasemtide' in epidermolysis bullosa and acute ischemic stroke patients, with the stroke trial failing to meet its primary endpoint.
Sep 9, 2026, 07:00 UTC
StemRim reported its fiscal year results for the year ended July 2026, with a net loss of 1.85 billion yen, narrowing from a 1.92 billion yen loss in the prior year, marking the third consecutive year of losses.
Jul 9, 2026, 22:32 UTC
Stemrim obtained a patent in South Korea for a stem cell gene therapy for epidermolysis bullosa.
Source: